Press Release Épalinges, Switzerland, August 28th, 2026 Developed on US claims, validated on external ICU data and against independent
Volv Global is pleased to be joining a panel discussion hosted by Innovaud on 15 September in Hammersmith, West London,
Volv Global and CSL Behring at ERS Congress 2026: Can We Catch ARDS Before It Strikes? Volv Global is heading
AI Innovation in Real-World Evidence & Data Analytics Volv Global has been selected as a finalist in the 2026 Fierce
Press Release Épalinges, Switzerland, June 29th, 2026 In a collaboration with a leading global pharmaceutical company, Volv Global applied
By Léon Van Wouwe, Clinical Innovation Director, Volv Global ASCO 2026 produced landmark oncology data. The question no one
Press Release Épalinges, Switzerland, June 15th, 2026 Cross-industry white paper calls for three paradigm shifts to unlock orphan drug
Paradigm shifts and strategic recommendations from Volv Global, Sanofi, Fondation Ipsen, Unitechpharma, and brave2change Orphan drug development faces barriers: approximately
Pompe disease is a rare, chronically debilitating metabolic disorder caused by deficiency of the enzyme acid alpha-glucosidase. As enzyme replacement
Press Release Épalinges, Switzerland, June 1st, 2026 Machine Learning Maps and Discovers Clinical Endpoints in Pompe Disease Using Real-World
Tech Tour Growth Health is one of Europe’s most established gatherings at the intersection of healthcare innovation and investment –
Volv Global is pleased to be participating in the Life Sciences Innovation & Investment Corridor between Lausanne & London, hosted
